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 41 
ABSTRACT  42 
Background context: Metastatic spine tumour surgery (MSTS) is associated with substantial blood 43 
loss therefore leading to high morbidity and mortality. While intraoperative cell salvage with 44 
leucocyte depletion filter  (IOCS-LDF) has been studied as an effective mean of reducing blood loss 45 
in other surgical settings, including the spine, no study has yet analysed the efficacy of re-infusion of 46 
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salvaged blood in reducing the need for allogenic blood transfusion in patients who have had surgery 1 
for MSTS. 2 
Purpose: To analyse the efficacy, safety and cost effectiveness of using IOCS-LDF in MSTS. 3 
Study design/ Setting: Retrospective controlled study 4 
Patient sample: 176 patients undergoing MSTS 5 
Methods: All patients undergoing MSTS at a single centre between February 2010 and December 6 
2014  were included in the study. The primary outcome measure was the use of autologous blood 7 
transfusion. Secondary outcome measures included hospital stay, survival time, complications and 8 
procedural costs. The key predictor variable was whether or not IOCS-LDF was utilised during 9 
surgery. Logistic and linear regression analyses were conducted by controlling variables such as 10 
tumour type, number of diseased vertebrae, approach, number and site of stabilised segments, 11 
operation time, pre-operative anaemia, ASA grade, age, gender and BMI.  No funding was obtained 12 
and there are no conflicts of interest to be declared. 13 
Results: Data included 63 cases (IOCS-LDF) and 113 controls (non IOCS-LDF). IOCS-LDF 14 
utilisation was substantively and significantly associated with a lower likelihood of allogenic blood 15 
transfusion (OR=0.407, p=0.03). IOCS-LDF was cost neutral (p=0.88).   Average hospital stay was 16 
3.76 days shorter amongst IOCS-LDF patients (p=0.03).  Patient survival and complication rates were 17 
comparable in both groups. 18 
Conclusions: We have demonstrated that the use of IOCS-LDF in MSTS reduces the need for post-19 
operative allogenic blood transfusion whilst maintaining satisfactory post-operative haemoglobin.   20 
We recommend routine use of IOCS-LDF in MSTS for its safety, efficacy and potential cost benefit. 21 
 22 
Keywords: "intraoperative cell salvage", "intraoperative blood salvage autotransfusion", "autologous 23 
transfusion", "autotransfusion", "malignant tumour", "tumour surgery", "cell saver", "blood loss in 24 
spinal metastatic surgeries, and "leucocyte depletion filter"  25 
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INTRODUCTION 1 
 2 
Metastatic spine tumour surgery (MSTS) aims to decompress neural structures, preserve cord 3 
function, stabilise the spine and confirm diagnosis prior to further oncological treatment. Whilst 4 
recent advances in perioperative care, spinal instrumentation and surgical techniques have led to 5 
improved clinical outcomes in MSTS, the peri-operative and postoperative risks remain high.[1, 2] 6 
Surgical treatment of MSTS is often associated with substantial blood loss and need for autologous 7 
blood transfusion, both of which contribute to high morbidity and potential mortality associated with 8 
these surgeries. In a meta-analysis published in 2013,Chen et al[3] found a mean blood loss of 2180ml 9 
in spinal tumour surgeries with a possibility of catastrophic blood loss of more than 5000ml in 12% of 10 
patients.[3] 11 
A number of peri- and intra-operative strategies exist to reduce the risk of blood loss.  Their aim is to 12 
minimize the need for allogeneic blood product transfusion, decrease total blood loss, and reduce cost. 13 
[4]  Additionally, they maintain high/adequate post-operative haemoglobin which potentially benefits 14 
patient recovery and could affect postoperative complication rates.[5] 15 
Intraoperative cell salvage (IOCS) involves the collection of shed surgical blood, filtration, and 16 
reinfusion to the patient and reduces the need of allogeneic blood transfusion.[6]  It has been 17 
demonstrated to be a viable option for reduction or avoidance of allogeneic blood product during 18 
many oncologic surgeries and may be a lifesaving option for patients who refuse allogeneic blood 19 
products.[7] 20 
The use of IOCS has been investigated in other oncological surgeries.  In gynaecology, hepatic, 21 
urological and cardiothoracic setting it has been demonstrated as being safe and efficacious in 22 
reducing allogeneic blood transfusion.[6-8] 23 
Although IOCS provides benefits, it carries some risks. In paediatric patients transient haematuria, 24 
concern for reinfusion of heparinized blood leading to altered haemostasis and alteration in electrolyte 25 
balance have been reported.   Furthermore, IOCS is potentially costly, and requires additional 26 
personnel intraoperatively.[7] 27 
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In oncological surgeries, efficacy of using the leucocyte depletion filter (LDF) to remove malignant 1 
cells from intra-operative cell salvage blood has been studied in vitro and in vivo and reported as a 2 
potentially safe.[9]  Previous studies have also evaluated the effectiveness of using IOCS with LDF to 3 
eliminate tumour cells from salvaged blood in spinal tumour surgeries[10, 11].  However no large 4 
scale comparative studies have been published to evaluate the efficacy in reducing the need for 5 
autologous blood transfusion or cost effectiveness in spinal tumour surgery.[12]  6 
In a systematic review published in 2014, Kumar et al suggested that the evidence base [10, 11] in 7 
other oncological surgeries would support the use of IOCS in MSTS but recognised the lack of 8 
evidence in this particular patient group.[12] 9 
The aim of this study was to evaluate the safety, efficacy and cost effectiveness of IOCS in MSTS. 10 
 11 
METHODS 12 
 13 
Data was retrospectively obtained from studying all patients undergoing MSTS at a single tertiary 14 
referral centre between February 2010 and December 2014.  Case notes and electronic inpatient 15 
hospital records were reviewed.  All disease related, patient related, surgery related and post-operative 16 
charts were reviewed to complete the data. 17 
Logistic and linear regression analyses were conducted, considering whether or not an allogenic blood 18 
transfusion was given and post-operative haemoglobin levels as primary outcome measures. 19 
Secondary outcome measures included length of stay, post-operative survival time, complications and 20 
procedural costs.  The key predictor variable was whether or not IOCS-LDF was utilised during the 21 
surgical procedure.  22 
A number of procedural-related, health-related and demographic variables were also initially 23 
considered as controlling variables for the primary analyses. Procedural-related variables were: type 24 
of tumour (categorised as thyroid/renal or non-thyroid/renal); number of vertebrae (affected spinal 25 
levels in the operative field); anatomical region (cervical, cervicothoracic, thoracic, thoracolumbar or 26 
lumbar); approach (posterior, anterior or combined); number of stabilised spinal levels and operation 27 
time.  Health-related variables were: pre-operative anaemia and ASA (American Society of 28 
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Anaesthesiologists) grade.[13]  Demographic variables were: age; gender and body mass index 1 
(BMI).  2 
Data was summarised descriptively. Exploratory procedures were undertaken to assess data 3 
distributions, extent of missing data and possible collinearity. 4 
Logistic regression analyses were conducted using the allogenic blood transfusion outcome measure.  5 
A sequential modelling strategy was utilised with the key predictor variable of IOCS-LDF utilisation 6 
included at the highest level of the model hierarchy. All procedural-related variables were then fitted 7 
at the second stage of the hierarchy. Health-related variables, ASA grade and anaemia status were 8 
fitted at the third level of the hierarchy.  Demographic variables of age, gender and BMI were fitted at 9 
the fourth (lowest) level of the hierarchy.  For hierarchical levels 2-4, stepwise routines were utilised 10 
to derive an optimum selection of variables within the level.  Final model adequacy was assessed 11 
using Nagelkerke’s pseudo-R2 statistic, and the percentage of cases correctly classified by the model 12 
was evaluated.  13 
Linear regression analyses were conducted on the data using the post-operative haemoglobin level 14 
outcome measure utilising the same sequential modelling strategy as for the sequential logistic 15 
regression modelling.  Cross-validation and diagnostic procedures were conducted on both of the final 16 
logistic and linear regression models.  17 
Secondary outcomes were assessed using descriptive and univariable methods. Association between 18 
IOCS-LDF group and patient survival was assessed using the χ2 test for association.  Associations 19 
between IOCS-LDF group, length of hospital stay and total procedural costs were assessed using 20 
independent samples t-test.  21 
Cost calculation was performed analysing the combined cost of use of IOCS-LDF equipment and cost 22 
of allogenic blood.  23 
 24 
 25 
RESULTS 26 
 27 
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Analysis was conducted on 176 patients, from an original dataset of 178 patients.  Two patients were 1 
not assigned to an IOCS-LDF group and were excluded from the analysis.  Less than 0.5% of the 2 
remaining data in total was missing, and imputation methods were not used. 3 
Data comprised 63 cases (use of IOCS-LDF) (35.8%of valid cases) and 113 controls (no use of IOCS-4 
LDF) (64.2%of valid cases). Dataset included 106 males (60.2%) and 70 females (39.8%); with a 5 
mean age of 63.2 years (SD 12.6 years) (Table 1). 6 
Exploratory analyses indicated evidence for collinearity effects between certain variables 7 
necessitating the removal of variables corresponding to number of affected vertebrae and anatomical 8 
region from subsequent analyses.  9 
 10 
Analysis of need for allogenic blood transfusion outcome 11 
Using the stepwise modelling strategy within each level of a sequential logistic regression procedure, 12 
the Level-2 variable corresponding to approach and stabilised levels entered the model at the 2
nd
 step, 13 
following the forced entry of the key predictor  variable of  IOCS-LDF at step 1. No other variables 14 
were included in the model at this step. Both Level-3 variables (ASA grade and preoperative anaemia) 15 
were included in the model at the 3
rd
 step. None of the Level-4 variables (demographic variables) 16 
were included in the model at the 4
th
 step. Hence, the final model included the variables IOCS-LDF, 17 
approach, number of stabilised levels, ASA grade and preoperative anaemia (Table 2).  18 
IOCS-LDF was found to be substantively and significantly associated with this outcome, as were 19 
number of stabilised levels, anaemia status and ASA grade. Approach was substantively associated 20 
with the need for allogenic blood transfusion but did not achieve statistical significance at the 5% 21 
level.  22 
Controlling for other variables, the odds of a patient receiving an allogenic blood transfusion were 23 
59% higher in cases where IOCS-LDF was not utilised than when it was utilised. A higher probability 24 
of allogenic blood transfusion was found in patients whose procedures involved anterior, rather than 25 
posterior approach (not statistically significant), greater extents of spinal fixation, higher ASA grades 26 
(indicating worse morbidity) and preoperative anaemia.  27 
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Nagelkerke’s pseudo-R2 statistic for the parsimonious model was 0.276, indicating that the model is a 1 
good fit to the data.  The model correctly classified 73.4% of cases in the sample. A model derived 2 
from a training set comprising 80% of cases correctly classified 70.0% of cases in a validation set 3 
comprising the remaining 20% of the sample; indicating good predictive capability.  Studentised 4 
residuals and Cook’s distances were within expectations for all cases, indicating that no data point 5 
exerts excessive influence on the model. 6 
 7 
Analysis of post-operative haemoglobin outcome 8 
Using the stepwise modelling strategy within each level of a sequential regression procedure, the 9 
Level-2 variable corresponding to stabilised levels entered the model at the second step, following the 10 
forced entry of the key predictor variable of IOCS-LDF at step 1. The Level-3 variable corresponding 11 
to anaemia entered the model at the 3
rd
 step. The Level-4 demographic variable gender was included 12 
in the model at the 4
th
 step. Hence the final model included the variables IOCS-LDF, stabilised levels, 13 
anaemia and gender (Table 3). 14 
While the controlling variables corresponding to number of stabilised levels, anaemia and gender 15 
were found to be significantly associated with the outcome, the IOCS-LDF variable did not achieve 16 
statistical significance at the 5% level, or appear to show any substantive importance.  Higher post-17 
operative haemoglobin levels were found in patients whose procedures involved lesser extents of 18 
spinal fixation, in those without anaemia and in males.  Controlling for other variables, an increase of 19 
one stabilised level was associated with a decreased post-operative haemoglobin count of 1.55 units; 20 
pre-operatively anaemic patients had 6.9 units post-operative haemoglobin count less than non-21 
anaemic patients; and male patients had 8.7 units post-operative haemoglobin count greater than 22 
female. 23 
The adjusted (Wherry) R
2
 value for the final model was 0.111. Stein’s adjusted R2 statistic for the 24 
final model was 0.0863; indicating an adequately performing model with good cross validity 25 
predictive power.   Studentised residuals and Cook’s distances were within expectations for all cases, 26 
indicating that no data point exerts excessive influence on the model.  No evidence for violation of 27 
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regression assumptions was detected during residual analysis procedures: residuals were found to be 1 
normally distributed and homogeneity of variance was achieved. 2 
 3 
Analyses of secondary outcomes 4 
The association between patient survival and IOCS-LDF was not significant using a χ2 test for 5 
association (χ2(1)=0.245; p=0.620).  Length of stay was 3.76 days shorter on average amongst those 6 
for whom IOCS-LDF was utilised (15.9 days) than amongst those for whom IOCS-LDF was not 7 
utilised (19.1 days).  This difference was statistically significant using an independent samples t-test 8 
(p=0.028). A 95% confidence interval for the difference was given by (0.34, 6.01).  9 
IOCS-LDF costs £128.41 per case.  The cost of the allogenic blood is £135.7 for a red blood cell unit, 10 
£215.03 for a platelets unit and £29.11 for a unit of fresh frozen plasma. The total procedural cost for 11 
patients for whom cell salvage was utilised and for whom IOCS-LDF was not utilised was not 12 
significantly different using an independent samples t-test (p=0.875). 13 
No difference in the peri and post-operative complications was found between the two groups. 14 
 15 
 16 
DISCUSSION 17 
 18 
Blood loss in MSTS is a major complication due to the tumour nature or altered spinal vascular 19 
anatomy (dilated epidural veins, hypervascularity and neovascularisation). Controlling blood loss is 20 
difficult.  To date, very little evidence exists to support the use of IOCS-LDF in MSTS. [14-16] 21 
Blood loss can affect patient recovery, delay wound healing and increase the risk of wound infection, 22 
ultimately delaying further oncological (radio or chemotherapy) treatment, increasing hospital stay 23 
and adding to healthcare costs.[17] 24 
The evaluation of the efficacy of blood conservation techniques in MSTS is compounded by many 25 
factors that can influence blood loss. These include type of primary tumour (non vascular/vascular), 26 
number of affected segments, number of operated levels, operative time and approach. Additionally, 27 
health related factors such as pre-operative anaemic status of the patients, ASA grading and BMI are 28 
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also variables that can potentially influence blood loss.  This is, to our knowledge, the first study to 1 
comprehensively consider and control for these confounding factors in evaluating the use of IOCS-2 
LDF in MSTS.  3 
All of these factors have been previously demonstrated as potentially affecting blood loss; Zhenget 4 
al[18] reported the factors affecting blood loss and blood transfusion in patients having segmental 5 
spinal surgeries as number of levels fused, age, and low preoperative haemoglobin.  Many studies 6 
have validated to role of BMI and ASA grade as factors which affect intraoperative blood loss.  7 
Therefore, in analysing the benefits of intraoperative cell salvage we have controlled for these 8 
potentially confounding factors in order to accurately establish the efficacy of IOCS-LDF in reducing 9 
the need for allogenic blood transfusion[19-23]. 10 
The choice of surgical approach is dependent upon the source of compression (anterior or posterior), 11 
patient comorbidity, associated deformity, surgeon’s experience and spinal instability.  Cases with 3-12 
column spinal disease, compression, deformity (kyphosis) and instability can require combined, 13 
anterior and posterior, decompression and stabilisation. These procedures are associated with 14 
significantly greater morbidity and blood loss, therefore have been controlled for in the analyses.[24-15 
26] 16 
To our knowledge, to date, no studies have analysed the cost-effectiveness of IOCS-LDF in MSTS. 17 
However, in liver transplant and hepatocellular carcinoma it has been found to be cost-effective.[27, 18 
28].  Ubeeetal [29] concluded that the cost benefits of IOCS make this technique economically 19 
efficient, clinically effective and an attractive alternative to other methods of transfusion for open 20 
radical prostatectomy surgery.[29]  Our results show that using IOCS-LDF is potentially cost neutral.  21 
The total procedural cost for patients for whom IOCS-LDF was utilised and for whom IOCS-LDF 22 
was not utilised was found to be not significantly different.  However our study did not include the 23 
additional staff cost that can be assicated with use of IOCS-LDF.   24 
The short hospital stay is an important focus of modern hospital management with associated 25 
reduction in cost and improvements the quality of health care.  Our results show that using IOCS is 26 
consistent with a reduced hospital stay.  Whilst this difference was observed and significant, it is 27 
likely that unmeasured factors, rather than the utilisation of IOCS-LDF, have contributed to this 28 
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finding (for example, patients’ neurological status).  In our study no association was found between 1 
patient survival and IOCS-LDF. 2 
Whilst our data was analysed retrospectively, missing data was minimal and with the substantial 3 
number of patients and an analysis that controls for the majority of the known and measurable 4 
confounding factors that can influence blood loss in this type of surgery, our findings would suggest 5 
that the routine use of IOCS-LDF in MSTS has clear benefits for both patients and healthcare 6 
providers.  7 
The National Institute for Health and Care Excellence (NICE) published guidelines endorsing the use 8 
of IOCS-LDF for radical prostatectomy and cystectomy.[30]  We would advise, based on our 9 
findings, the routine use of IOCS-LDF in MSTS. 10 
 11 
CONCLUSION 12 
 13 
In summary we have demonstrated that the use of IOCS-LDF in MSTS reduces the need for post-14 
operative allogenic blood transfusion whilst maintaining satisfactory post-operative haemoglobin. The 15 
use of IOCS-LDF may be cost-effective depending on the personnel set-up.  We would recommend 16 
routine use of IOCS-LDF in MSTS for its safety and efficacy.  17 
 18 
 19 
  20 
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Table 1: descriptive summary of cohort 1 
Variable Cases (n=63) Controls (n=113) All patients (n=176) 
Gender 
   Males (frequency (valid %)) 
   Females (frequency (valid %)) 
 
45 (71.4%) 
18 (28.6%) 
 
61 (54.0%) 
52 (46.0%) 
 
106 (60.2%) 
70 (39.8%) 
Age (mean (SD)) 63.6 (13.8) 64.1 (11.5) 63.6 (12.6) 
BMI (mean (SD)) 25.9 (4.55) 25.7 (4.58) 25.8 (4.54) 
Number of affected vertebrae (median (range)) 1 (1-7) 1 (1-4) 1 (1-7) 
Number of stabilised levels (median (range)) 4 (2-12) 4 (0-11) 4 (0-12) 
Operation time (hours) (mean (SD)) 4.64 (1.66) 4.04 (1.54) 4.26 (1.62) 
ASA score (median (range)) 3 (1-5) 3 (1-5) 3 (1-5) 
Length of stay in days (mean (SD)) 15.9 (7.38) 19.1 (9.96) 17.9 (9.19) 
Type of tumour 
   Non-thyroid/renal (frequency (valid %)) 
   Thyroid/renal (frequency (valid %)) 
 
53 (86.9%) 
8 (13.1%) 
 
105 (93.8%) 
7 (6.2%) 
 
158 (91.3%) 
15 (8.7%) 
Approach 
   Posterior only (frequency (valid %)) 
   Anterior/both (frequency (valid %)) 
 
51 (81.0%) 
12 (19.0%) 
 
96 (85.0%) 
17 (15.0%) 
 
147 (83.5%) 
29 (16.5%) 
Level code 
Cervical (frequency (valid %)) 
Cervicothoracic (frequency (valid %)) 
Thoracic (frequency (valid %)) 
Thoracolumbar (frequency (valid %)) 
Lumbar (frequency (valid %)) 
 
3 (4.8%) 
7 (11.1%) 
28 (44.4%) 
16 (25.4%) 
9 (14.3%) 
 
11 (9.7%) 
9 (8.0%) 
52 (46.0%) 
35 (31.0%) 
5 (5.3%) 
 
14 (8.0%) 
16 (9.1%) 
80 (45.5%) 
51 (29.0%) 
15 (8.5%) 
Preoperative anaemia  
   No anaemia (frequency (valid %)) 
   Anaemia (frequency (valid %)) 
 
29 (46.0%) 
34 (53.0%) 
 
58 (51.3%) 
55 (48.7%) 
 
87 (49.4%) 
89 (50.6%) 
Surgical complications 
   No complications (frequency (valid %)) 
   Complications (frequency (valid %)) 
 
59 (95.2%) 
3 (4.8%) 
 
107 (99.1%) 
1 (0.9%) 
 
166 (97.6%) 
4 (2.4%) 
Patient survival 
   Death recorded (frequency (valid %)) 
   No death recorded (frequency (valid %)) 
 
26 (41.3%) 
37 (58.7%) 
 
51 (45.1%) 
62 (54.9%) 
 
77 (43.8%) 
99 (56.2%) 
Procedural cost (mean (SD)) GBP351.78 
(GBP207.21) 
GBP338.42 
(GBP314.85) 
GBP340.77 (GBP286.67) 
  2 
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Table 2: Parameter coefficients, confidence intervals and p-values of all variables included in final model 1 
(blood transfusion outcome measure) 2 
Variable Parameter estimate Odds ratio (OR) 95% confidence interval for OR P-value 
IOCS-LDF -0.898 0.407 (0.180, 0.920) 0.031 
Approach1 0.923 2.516 (0.866, 7.304) 0.090 
Number of stabilised  
levels  
0.408 1.503 (1.221, 1.852) <0.001 
Anaemia status2 1.042 2.836 (1.337, 6.016) 0.007 
ASA grade 0.806 2.239 (1.244, 4.031) 0.007 
1
Reference category=posterior approach 3 
2
Reference category=no anaemia 4 
 5 
 6 
 7 
Table 3: Parameter coefficients, confidence intervals and p-values of all variables included in final model 8 
(post-operative haemoglobin outcome measure) 9 
Variable Unstandardised coefficient 95% confidence interval P-value 
IOCS-LDF -1.568 (-6.708, 3.572) 0.548 
stabilised levels  -1.553 (-2.778, -0.328) 0.013 
Anaemia1 -6.892 (-11.81, -1.97) 0.006 
Gender2 -8.692 (-13.77, -3.61) 0.001 
1
Reference category=no anaemia 10 
2
Reference category=male
 11 
 12 
 13 
 14 
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